H. Lundbeck A/S

In News

Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal - Reuters

Reuters - Oct 14, 2024

H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement - simplywall.st

simplywall.st - May 28, 2025

Revenue of Lundbeck from 2009 to 2024 - Statista

Statista - Feb 12, 2025

H. Lundbeck A/S : Lundbeck - MarketScreener

MarketScreener - Nov 20, 2024

H. Lundbeck A/S: New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Finansavisen

Finansavisen - Jun 21, 2025

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - Business Wire

Business Wire - Oct 14, 2024

Lundbeck to take over Longboard Pharma in US$2.6bn transaction - European Biotechnology Magazine

European Biotechnology Magazine - Oct 15, 2024

Lundbeck successfully places a EUR 500 million Eurobond - TradingView

TradingView - May 22, 2025

Lundbeck reports orexin OX2 receptor agonists - BioWorld MedTech

BioWorld MedTech - Dec 30, 2024

Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal - BNN Bloomberg

BNN Bloomberg - Oct 14, 2024

H. Lundbeck A/S: Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia - Finansavisen

Finansavisen - Jun 24, 2025

Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies - Wiley Online Library

Wiley Online Library - Aug 29, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.